Aller au contenu principal
Accès ouvert déclaré 2025 review

The association between depressive symptom severity and metabolic disturbances in major depressive and bipolar disorders: A systematic review and meta-analysis

2Citations signalées, ce qui n’est pas une note de qualité
6Institutions déclarées
5Pays d’affiliation déclarés

Rattachement africain : ca, co, sg, hk, cn. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

BACKGROUND: Persons with depression are differentially affected by metabolic alterations, notably, insulin resistance and dyslipidemia. Metabolic alterations affect acute pharmacotherapy response and predispose risk for cardiovascular diseases. We aimed to extend knowledge pertaining to the depression-metabolic alteration association by evaluating whether depressive symptom severity moderates the association. METHODS: We conducted a systematic search of PubMed, Ovid and Scopus from inception to May 2025. Two reviewers (S.W. and G.H.L.) independently screened the identified studies. Studies were included if they enrolled adults with depression and reported on at least one metabolic parameter (i.e., fasting glucose, insulin, lipid panels). Standardized mean differences of metabolic parameters were pooled across studies. RESULTS: We identified 28 studies for inclusion. Persons with depression exhibited higher fasting glucose (SMD = 0.30, 95 % CI [0.12, 0.48]) and dyslipidemia [i.e., trends of increased low-density lipoprotein (SMD = 0.21, 95 % CI [-0.03, 0.44]) and lower high-density lipoprotein (SMD = -0.72, 95 % CI [-1.41, -0.03])]. Measures of insulin resistance were positively associated with anhedonia severity, sleep disturbances, and suicidal ideation. LIMITATIONS: Between-study methodological differences, including study design and sociodemographics, affects the synthesis of overall trends. CONCLUSION: Herein, we identify an association between depressive symptom severity and dysglycemia, dyslipidemia and insulin resistance. The results augment the conceptual framework implicating metabolic disturbances in depression pathophysiology and indirectly support testing that therapeutics currently in development in the treatment of depression (e.g., GLP-1 receptor agonists) may exhibit differential efficacy as a function of illness severity.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
The association between depressive symptom severity and metabolic disturbances in major depressive and bipolar disorders: A systematic review and meta-analysis
Date Crossref
01/02/2026
Éditeur
Elsevier BV
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Les institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Bipolar Disorder and TreatmentTreatment of Major DepressionTryptophan and brain disorders

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.